OCREVUS ZUNOVO
GrowthmAbBLAINJECTIONINJECTABLE
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
OCREVUS ZUNOVO by Roche is unknown, but is presumed to involve binding to cd20, a cell surface antigen present on pre-b and mature b lymphocytes. First approved in 2024.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OCREVUS ZUNOVO is a subcutaneous formulation combining ocrelizumab (a CD20-directed monoclonal antibody) with hyaluronidase, approved September 2024 for CD20+ B-cell malignancies and autoimmune indications. The hyaluronidase enhances subcutaneous delivery, improving patient convenience and potentially reducing infusion burden compared to the intravenous OCREVUS. This represents a formulation advancement within Roche's established CD20 antibody franchise.
Growth
Early-stage commercial launch with growth trajectory; teams will scale launch infrastructure, market access, and field force to capture conversion from IV OCREVUS formulation.
Mechanism of Action
unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ocrelizumab results in antibody-dependent cellular cytolysis and complement-mediated lysis. Hyaluronan is a polysaccharide found in…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Ocrevus Zunovo for MS: Mixed Methods
Started Jun 2026
150 enrolled
Multiple Sclerosis
Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714
Started Nov 2018
51 enrolled
Multiple SclerosisRelapsePrimary Progressive Multiple Sclerosis
Worked on OCREVUS ZUNOVO at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.